ClinicalTrials.gg
CompletedNCT00867165Updated May 21, 2024Results posted

Pediatric Study to Evaluate the Efficacy and Safety of Ezetimibe Monotherapy in Children With Primary Hypercholesterolemia (P05522)

A Phase 3 interventional study of ezetimibe and Placebo in Primary Hypercholesterolemia, sponsored by Organon and Co. Completed. Open to participants aged 6 Years to 10 Years. Per ClinicalTrials.gov, last updated 2024-05-21.

Sponsored by Organon and Co · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
138
Allocation
Randomized
Ages
6 Years to 10 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 98 studies testing ezetimibe in Hypercholesterolemia — 3 open to participants now, 4 under way, 1 of them phase 3. Ezetimibe · Hypercholesterolemia.

Enrollment
52nd of 97
138 · median 148
Started
2009
with 5 others
Phase 3
50 of 98
1 open now
Registered
58th of 98
by date
Lead sponsor
55 of 98
Organon and Co

Among the 98 studies testing ezetimibe in Hypercholesterolemia, this one is the 52nd largest by enrollment of the 97 interventional ones that give a count, is one of 6 that started in 2009, is one of 50 in phase 3, and was the 58th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

3 of the 98 studies testing ezetimibe in Hypercholesterolemia are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ezetimibe

Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 6 Years to 10 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing ezetimibe in Hypercholesterolemia, or all of them as a file.
02

Study summary

The purpose of this study is to determine the effect of ezetimibe 10 mg/day compared to placebo on the reduction of low-density lipoprotein cholesterol (LDL-C) from baseline to 12 weeks of treatment in children >=6 to \<=10 years old with primary hypercholesterolemia. The study will also evaluate the effect of ezetimibe on total cholesterol (TC), apolipoprotein B (Apo B), high-density lipoprotein cholesterol (HDL-C), non-HDL-C, and triglycerides (TG). The safety of ezetimibe in this subject population will also be evaluated.

03

Conditions studied

  • Primary Hypercholesterolemia

Keywords

  • heterozygous familial hypercholesterolemia
  • nonfamilial hypercholesterolemia
04

Who can participate

Ages eligible
6 Years to 10 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Each subject may be of either sex and of any race/ethnicity, and must be >=6 and \<=10 years of age, with a diagnosis of primary hypercholesterolemia (heterozygous familial or nonfamilial) despite being on a lipid-lowering diet for at least 3 months with a LDL-C of >159mg/dL
  • Each subject's parent/guardian must be willing to give written on his/her behalf.

Exclusion criteria

Exclusion Criteria:

Each subject must not:

  • Have known or any to ezetimibe.
  • Have use of any drugs within 30 days of study entry.
  • Be a member or a family member of the personnel of the investigational or sponsor staff directly involved with this trial.
  • Be a female of who is pregnant, intends to become pregnant, or is nursing
  • Have known congenital cardiac disorder.
  • Have documented or laboratory values consistent with homozygous familial hypercholesterolemia (HoFH).
  • Be known to be (HIV) positive.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
138 participants (actual)

Study arms

  • Experimental
    Ezetimibe

    Ezetimibe 10-mg tablet once daily for 12 weeks

    Drug: ezetimibe

  • Placebo comparator
    Placebo

    Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks

    Drug: Placebo

Interventions

  • oral tablets: ezetimibe 10 mg once daily for 12 weeks

    Also known as: SCH 58235, MK-0653, Zetia

  • DrugPlacebo

    oral tablets: placebo to match ezetimibe 10 mg; administered once daily during the 5-week, single-blind, placebo run-in and diet stabilization period and 12-week double-blind treatment period

06

What researchers measure

Primary outcomes

  1. Percentage Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12

    Serum LDL-C levels calculated at baseline and after 12 weeks of study drug administration. LDL-C were calculated by the method of Friedewald equation, LDL-C = Total Cholesterol (TC) - (High-density lipoprotein cholesterol \[HDL-C\] + triglyceride \[TG\]/5).

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Percentage Change From Baseline in Total Cholesterol (TC) at Week 12

    Serum TC levels measured using enzymatic methods at baseline and after 12 weeks of study drug administration.

    Time frame: Baseline and Week 12

  2. Percentage Change From Baseline in Apolipoprotein B (Apo B) at Week 12

    Serum Apo B measured at baseline and after 12 weeks of study drug administration.

    Time frame: Baseline and Week 12

  3. Percentage Change From Baseline High-density Lipoprotein Cholesterol (HDL-C) at Week 12

    Serum HDL-C levels measured by photometry after precipitation at baseline and after 12 weeks of study drug administration.

    Time frame: Baseline and Week 12

  4. Percentage Change From Baseline in Non-HDL-C at Week 12

    Serum Non-HDL-C calculated at baseline and after 12 weeks of study drug administration. Non-HDL-C values were calculated as follows: Non-HDL-C (mg/dL) = TC - HDL-C.

    Time frame: Baseline and Week 12

  5. Percentage Change From Baseline in Triglycerides (TG) at Week 12

    Serum TG levels measured using enzymatic methods at baseline and after 12 weeks of study drug.

    Time frame: Baseline and Week 12

  6. Percent Change From Baseline in LDL-C at Week 2

    Serum LDL-C levels calculated at baseline and after 2 weeks of study drug administration. LDL-C were calculated by the method of Friedewald equation, LDL-C = Total Cholesterol (TC) - (High-density lipoprotein cholesterol \[HDL-C\] + triglyceride \[TG\]/5).

    Time frame: Baseline and Week 2

  7. Percent Change From Baseline in LDL-C at Week 4

    Serum LDL-C levels calculated at baseline and after 4 weeks of study drug administration. LDL-C were calculated by the method of Friedewald equation, LDL-C = Total Cholesterol (TC) - (High-density lipoprotein cholesterol \[HDL-C\] + triglyceride \[TG\]/5).

    Time frame: Baseline and Week 4

  8. Percent Change From Baseline in LDL-C at Week 8

    Serum LDL-C levels calculated at baseline and after 8 weeks of study drug administration. LDL-C were calculated by the method of Friedewald equation, LDL-C = Total Cholesterol (TC) - (High-density lipoprotein cholesterol \[HDL-C\] + triglyceride \[TG\]/5).

    Time frame: Baseline and Week 8

  9. Percentage Change From Baseline in TC at Week 2

    Serum TC levels measured using enzymatic methods at baseline and after 2 weeks of study drug administration.

    Time frame: Baseline and Week 2

  10. Percentage Change From Baseline in TC at Week 4

    Serum TC levels measured using enzymatic methods at baseline and after 4 weeks of study drug administration.

    Time frame: Baseline and Week 4

  11. Percentage Change From Baseline in TC at Week 8

    Serum TC levels measured using enzymatic methods at baseline and after 8 weeks of study drug administration.

    Time frame: Baseline and Week 8

  12. Percentage Change From Baseline HDL-C at Week 2

    Serum HDL-C levels measured by photometry after precipitation at baseline and after 2 weeks of study drug administration.

    Time frame: Baseline and Week 2

  13. Percentage Change From Baseline HDL-C at Week 4

    Serum HDL-C levels measured by photometry after precipitation at baseline and after 4 weeks of study drug administration.

    Time frame: Baseline and Week 4

  14. Percentage Change From Baseline HDL-C at Week 8

    Serum HDL-C levels measured by photometry after precipitation at baseline and after 8 weeks of study drug administration.

    Time frame: Baseline and Week 8

  15. Percentage Change From Baseline in Non-HDL-C at Week 2

    Serum Non-HDL-C calculated at baseline and after 2 weeks of study drug administration. Non-HDL-C values were calculated as follows: Non-HDL-C (mg/dL) = TC - HDL-C.

    Time frame: Baseline and Week 2

  16. Percentage Change From Baseline in Non-HDL-C at Week 4

    Serum Non-HDL-C calculated at baseline and after 4 weeks of study drug administration. Non-HDL-C values were calculated as follows: Non-HDL-C (mg/dL) = TC - HDL-C.

    Time frame: Baseline and Week 4

  17. Percentage Change From Baseline in Non-HDL-C at Week 8

    Serum Non-HDL-C calculated at baseline and after 8 weeks of study drug administration. Non-HDL-C values were calculated as follows: Non-HDL-C (mg/dL) = TC - HDL-C.

    Time frame: Baseline and Week 8

  18. Percentage Change From Baseline in TG at Week 2

    Serum TG levels measured using enzymatic methods at baseline and after 2 weeks of study drug administration.

    Time frame: Baseline and Week 2

  19. Percentage Change From Baseline in TG at Week 4

    Serum TG levels measured using enzymatic methods at baseline and after 4 weeks of study drug administration.

    Time frame: Baseline and Week 4

  20. Percentage Change From Baseline in TG at Week 8

    Serum TG levels measured using enzymatic methods at baseline and after 8 weeks of study drug administration.

    Time frame: Baseline and Week 8

  21. Percentage Change From Baseline in Apolipoprotein A-I (Apo A-I) at Week 12

    Serum Apo A-I levels measured at baseline and after 12 weeks of study drug administration.

    Time frame: Baseline and Week 12

  22. Percentage Change From Baseline in TC:HDL-C Ratio at Week 2

    Serum TC:HDL-C Ratio calculated at baseline and after 2 weeks of study drug administration.

    Time frame: Baseline and Week 2

  23. Percentage Change From Baseline in TC:HDL-C Ratio at Week 4

    Serum TC:HDL-C Ratio calculated at baseline and after 4 weeks of study drug administration.

    Time frame: Baseline and Week 4

  24. Percentage Change From Baseline in TC:HDL-C Ratio at Week 8

    Serum TC:HDL-C Ratio calculated at baseline and after 8 weeks of study drug administration.

    Time frame: Baseline and Week 8

  25. Percentage Change From Baseline in TC:HDL-C Ratio at Week 12

    Serum TC:HDL-C Ratio calculated at baseline and after 12 weeks of study drug administration.

    Time frame: Baseline and Week 12

  26. Percentage Change From Baseline in LDL-C:HDL-C Ratio at Week 2

    Serum LDL-C:HDL-C Ratio calculated at baseline and after 2 weeks of study drug administration.

    Time frame: Baseline and Week 2

  27. Percentage Change From Baseline in LDL-C:HDL-C Ratio at Week 4

    Serum LDL-C:HDL-C Ratio calculated at baseline and after 4 weeks of study drug administration.

    Time frame: Baseline and Week 4

  28. Percentage Change From Baseline in LDL-C:HDL-C Ratio at Week 8

    Serum LDL-C:HDL-C Ratio calculated at baseline and after 8 weeks of study drug administration.

    Time frame: Baseline and Week 8

  29. Percentage Change From Baseline in LDL-C:HDL-C Ratio at Week 12

    Serum LDL-C:HDL-C Ratio calculated at baseline and after 12 weeks of study drug administration.

    Time frame: Baseline and Week 12

  30. Percentage Change From Baseline in Apo B:Apo A-I Ratio at Week 12

    Serum Apo B:Apo A-I Ratio calculated at baseline and after 12 weeks of study drug administration

    Time frame: Baseline and Week 12

  31. Percentage Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) at Week 4

    Plasma hs-CRP measured at baseline and after 4 weeks of study drug administration.

    Time frame: Baseline and Week 4

  32. Percentage Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) at Week 12

    Plasma hs-CRP measured at baseline and after 12 weeks of study drug administration.

    Time frame: Baseline and Week 12

  33. Percent Change From Baseline in Sitosterol at Week 2

    Plasma sitosterol measured at baseline and after 2 weeks of study drug administration.

    Time frame: Baseline and Week 2

  34. Percentage Change From Baseline in Sitosterol at Week 4

    Plasma sitosterol measured at baseline and after 4 weeks of study drug administration.

    Time frame: Baseline and Week 4

  35. Percentage Change From Baseline in Sitosterol at Week 8

    Plasma sitosterol measured at baseline and after 8 weeks of study drug administration.

    Time frame: Baseline and Week 8

  36. Percentage Change From Baseline in Sitosterol at Week 12

    Plasma sitosterol measured at baseline and after 12 weeks of study drug administration.

    Time frame: Baseline and Week 12

  37. Percentage Change From Baseline in Campesterol at Week 2

    Plasma campesterol measured at baseline and after 2 weeks of study drug administration.

    Time frame: Baseline and Week 2

  38. Percentage Change From Baseline in Campesterol at Week 4

    Plasma campesterol measured at baseline and after 4 weeks of study drug administration.

    Time frame: Baseline and Week 4

  39. Percentage Change From Baseline in Campesterol at Week 8

    Plasma campesterol measured at baseline and after 8 weeks of study drug administration.

    Time frame: Baseline and Week 8

  40. Percentage Change From Baseline in Campesterol at Week 12

    Plasma campesterol measured at baseline and after 12 weeks of study drug administration.

    Time frame: Baseline and Week 12

  41. Percentage Change From Baseline in Cholestanol at Week 2

    Plasma cholestanol measured at baseline and after 2 weeks of study drug administration.

    Time frame: Baseline and Week 2

  42. Percentage Change From Baseline in Cholestanol at Week 4

    Plasma cholestanol measured at baseline and after 4 weeks of study drug administration.

    Time frame: Baseline and Week 4

  43. Percentage Change From Baseline in Cholestanol at Week 8

    Plasma cholestanol measured at baseline and after 8 weeks of study drug administration.

    Time frame: Baseline and Week 8

  44. Percentage Change From Baseline in Cholestanol at Week 12

    Plasma cholestanol measured at baseline and after 12 weeks of study drug administration.

    Time frame: Baseline and Week 12

  45. Percentage Change From Baseline in Lathosterol at Week 2

    Plasma lathosterol measured at baseline and after 2 weeks of study drug administration.

    Time frame: Baseline and Week 2

  46. Percentage Change From Baseline in Lathosterol at Week 4

    Plasma lathosterol measured at baseline and after 4 weeks of study drug administration.

    Time frame: Baseline and Week 4

  47. Percentage Change From Baseline in Lathosterol at Week 8

    Plasma lathosterol measured at baseline and after 8 weeks of study drug administration.

    Time frame: Baseline and Week 8

  48. Percentage Change From Baseline in Lathosterol at Week 12

    Plasma lathosterol measured at baseline and after 12 weeks of study drug administration.

    Time frame: Baseline and Week 12

07

Results

Posted May 30, 2013

Participant flow

Participant flow — Overall Study
MilestoneEzetimibePlacebo
Started9345
Completed8945
Not completed40
Withdrew: Adverse event30
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryPercentage Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12

Serum LDL-C levels calculated at baseline and after 12 weeks of study drug administration. LDL-C were calculated by the method of Friedewald equation, LDL-C = Total Cholesterol (TC) - (High-density lipoprotein cholesterol \[HDL-C\] + triglyceride \[TG\]/5).

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Percent Change
Percentage Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12
Percent ChangeEzetimibePlacebo
Percentage Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12-27.70 (-30.80 to -24.59)-0.95 (-4.94 to 3.04)
Statistical analysis
  • Ezetimibe vs Placebo · ANCOVA · p = <0.001 · Difference in least-squares means: -26.74 · 95% CI -30.80 to -22.69
SecondaryPercentage Change From Baseline in Total Cholesterol (TC) at Week 12

Serum TC levels measured using enzymatic methods at baseline and after 12 weeks of study drug administration.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Percentage Change
Percentage Change From Baseline in Total Cholesterol (TC) at Week 12
Percentage ChangeEzetimibePlacebo
Percentage Change From Baseline in Total Cholesterol (TC) at Week 12-20.74 (-23.29 to -18.18)0.19 (-3.07 to 3.44)
Statistical analysis
  • Ezetimibe vs Placebo · ANCOVA · p = <0.001 · Difference in least-squares means: -20.92 · 95% CI -24.20 to -17.65
SecondaryPercentage Change From Baseline in Apolipoprotein B (Apo B) at Week 12

Serum Apo B measured at baseline and after 12 weeks of study drug administration.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Percent Change
Percentage Change From Baseline in Apolipoprotein B (Apo B) at Week 12
Percent ChangeEzetimibePlacebo
Percentage Change From Baseline in Apolipoprotein B (Apo B) at Week 12-21.66 (-24.94 to -18.38)-1.42 (-5.55 to 2.70)
Statistical analysis
  • Ezetimibe vs Placebo · ANCOVA · p = <0.001 · Difference in least-squares means: -20.24 · 95% CI -24.02 to -16.45
SecondaryPercentage Change From Baseline High-density Lipoprotein Cholesterol (HDL-C) at Week 12

Serum HDL-C levels measured by photometry after precipitation at baseline and after 12 weeks of study drug administration.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Percentage Change
Percentage Change From Baseline High-density Lipoprotein Cholesterol (HDL-C) at Week 12
Percentage ChangeEzetimibePlacebo
Percentage Change From Baseline High-density Lipoprotein Cholesterol (HDL-C) at Week 122.11 (-2.27 to 6.48)1.41 (-4.14 to 6.96)
Statistical analysis
  • Ezetimibe vs Placebo · ANCOVA · p = 0.807 · Difference in least-square means: 0.70 · 95% CI -4.97 to 6.36
SecondaryPercentage Change From Baseline in Non-HDL-C at Week 12

Serum Non-HDL-C calculated at baseline and after 12 weeks of study drug administration. Non-HDL-C values were calculated as follows: Non-HDL-C (mg/dL) = TC - HDL-C.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Percentage Change
Percentage Change From Baseline in Non-HDL-C at Week 12
Percentage ChangeEzetimibePlacebo
Percentage Change From Baseline in Non-HDL-C at Week 12-25.47 (-28.45 to -22.49)0.28 (-3.52 to 4.08)
Statistical analysis
  • Ezetimibe vs Placebo · ANCOVA · p = <0.001 · Differrence in least-squares means: -25.75 · 95% CI -29.59 to -21.91
SecondaryPercentage Change From Baseline in Triglycerides (TG) at Week 12

Serum TG levels measured using enzymatic methods at baseline and after 12 weeks of study drug.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Percentage change
Percentage Change From Baseline in Triglycerides (TG) at Week 12
Percentage changeEzetimibePlacebo
Percentage Change From Baseline in Triglycerides (TG) at Week 12-6.23 (-12.73 to 0.75)8.44 (-2.03 to 20.03)
Statistical analysis
  • Ezetimibe vs Placebo · Constrained longitudinal data analysis · p = 0.021 · Difference in least-square means: -14.68 · 95% CI -27.35 to -2.00
SecondaryPercent Change From Baseline in LDL-C at Week 2

Serum LDL-C levels calculated at baseline and after 2 weeks of study drug administration. LDL-C were calculated by the method of Friedewald equation, LDL-C = Total Cholesterol (TC) - (High-density lipoprotein cholesterol \[HDL-C\] + triglyceride \[TG\]/5).

Time frame:
Baseline and Week 2
Reported as:
Least squares mean · Percentage Change
Percent Change From Baseline in LDL-C at Week 2
Percentage ChangeEzetimibePlacebo
Percent Change From Baseline in LDL-C at Week 2-24.75 (-27.80 to -21.69)0.23 (-3.74 to 4.20)
Statistical analysis
  • Ezetimibe vs Placebo · ANCOVA · p = <0.001 · Difference in least-squares means: -24.97 · 95% CI -28.95 to -20.99
SecondaryPercent Change From Baseline in LDL-C at Week 4

Serum LDL-C levels calculated at baseline and after 4 weeks of study drug administration. LDL-C were calculated by the method of Friedewald equation, LDL-C = Total Cholesterol (TC) - (High-density lipoprotein cholesterol \[HDL-C\] + triglyceride \[TG\]/5).

Time frame:
Baseline and Week 4
Reported as:
Least squares mean · Percentage Change
Percent Change From Baseline in LDL-C at Week 4
Percentage ChangeEzetimibePlacebo
Percent Change From Baseline in LDL-C at Week 4-26.93 (-29.81 to -24.05)-2.99 (-6.66 to 0.68)
Statistical analysis
  • Ezetimibe vs Placebo · ANCOVA · p = <0.001 · Difference in least-square means: -23.94 · 95% CI -27.49 to -20.39
SecondaryPercent Change From Baseline in LDL-C at Week 8

Serum LDL-C levels calculated at baseline and after 8 weeks of study drug administration. LDL-C were calculated by the method of Friedewald equation, LDL-C = Total Cholesterol (TC) - (High-density lipoprotein cholesterol \[HDL-C\] + triglyceride \[TG\]/5).

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · Percentage Change
Percent Change From Baseline in LDL-C at Week 8
Percentage ChangeEzetimibePlacebo
Percent Change From Baseline in LDL-C at Week 8-27.22 (-30.30 to -24.15)0.49 (-3.46 to 4.43)
Statistical analysis
  • Ezetimibe vs Placebo · ANCOVA · p = <0.001 · Difference in least-squares means: -27.71 · 95% CI -31.70 to -23.73
SecondaryPercentage Change From Baseline in TC at Week 2

Serum TC levels measured using enzymatic methods at baseline and after 2 weeks of study drug administration.

Time frame:
Baseline and Week 2
Reported as:
Least squares mean · Percentage Change
Percentage Change From Baseline in TC at Week 2
Percentage ChangeEzetimibePlacebo
Percentage Change From Baseline in TC at Week 2-18.69 (-21.21 to -16.18)1.40 (-1.83 to 4.63)
Statistical analysis
  • Ezetimibe vs Placebo · ANCOVA · p = <0.001 · Difference in least-squares means: -20.09 · 95% CI -23.30 to -16.89
SecondaryPercentage Change From Baseline in TC at Week 4

Serum TC levels measured using enzymatic methods at baseline and after 4 weeks of study drug administration.

Time frame:
Baseline and Week 4
Reported as:
Least squares mean · Percentage Change
Percentage Change From Baseline in TC at Week 4
Percentage ChangeEzetimibePlacebo
Percentage Change From Baseline in TC at Week 4-20.57 (-23.05 to -18.08)-0.29 (-3.45 to 2.86)
Statistical analysis
  • Ezetimibe vs Placebo · ANCOVA · p = <0.001 · Difference in least-squares means: -20.27 · 95% CI -23.39 to -17.15
SecondaryPercentage Change From Baseline in TC at Week 8

Serum TC levels measured using enzymatic methods at baseline and after 8 weeks of study drug administration.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · Percentage Change
Percentage Change From Baseline in TC at Week 8
Percentage ChangeEzetimibePlacebo
Percentage Change From Baseline in TC at Week 8-20.84 (-23.40 to -18.27)0.54 (-2.73 to 3.81)
Statistical analysis
  • Ezetimibe vs Placebo · ANCOVA · p = <0.001 · Difference in least-squares means: -21.37 · 95% CI -24.67 to -18.08
SecondaryPercentage Change From Baseline HDL-C at Week 2

Serum HDL-C levels measured by photometry after precipitation at baseline and after 2 weeks of study drug administration.

Time frame:
Baseline and Week 2
Reported as:
Least squares mean · Percentage Change
Percentage Change From Baseline HDL-C at Week 2
Percentage ChangeEzetimibePlacebo
Percentage Change From Baseline HDL-C at Week 20.01 (-4.28 to 4.30)0.96 (-4.51 to 6.43)
Statistical analysis
  • Ezetimibe vs Placebo · ANCOVA · p = 0.733 · Difference in least-squares means: -0.95 · 95% CI -6.46 to 4.55
SecondaryPercentage Change From Baseline HDL-C at Week 4

Serum HDL-C levels measured by photometry after precipitation at baseline and after 4 weeks of study drug administration.

Time frame:
Baseline and Week 4
Reported as:
Least squares mean · Percentage Change
Percentage Change From Baseline HDL-C at Week 4
Percentage ChangeEzetimibePlacebo
Percentage Change From Baseline HDL-C at Week 40.86 (-3.69 to 5.42)0.33 (-5.54 to 6.19)
Statistical analysis
  • Ezetimibe vs Placebo · ANCOVA · p = 0.863 · Difference in least-squares means: 0.53 · 95% CI -5.59 to 6.66
SecondaryPercentage Change From Baseline HDL-C at Week 8

Serum HDL-C levels measured by photometry after precipitation at baseline and after 8 weeks of study drug administration.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · Percentage Change
Percentage Change From Baseline HDL-C at Week 8
Percentage ChangeEzetimibePlacebo
Percentage Change From Baseline HDL-C at Week 81.41 (-2.95 to 5.77)-0.52 (-6.04 to 5.00)
Statistical analysis
  • Ezetimibe vs Placebo · ANCOVA · p = 0.501 · Difference in least-squares means: 1.92 · 95% CI -3.71 to 7.56
SecondaryPercentage Change From Baseline in Non-HDL-C at Week 2

Serum Non-HDL-C calculated at baseline and after 2 weeks of study drug administration. Non-HDL-C values were calculated as follows: Non-HDL-C (mg/dL) = TC - HDL-C.

Time frame:
Baseline and Week 2
Reported as:
Least squares mean · Percentage Change
Percentage Change From Baseline in Non-HDL-C at Week 2
Percentage ChangeEzetimibePlacebo
Percentage Change From Baseline in Non-HDL-C at Week 2-22.54 (-25.41 to -19.67)1.64 (-2.03 to 5.30)
Statistical analysis
  • Ezetimibe vs Placebo · ANCOVA · p = <0.001 · Difference in least-squares means: -24.18 · 95% CI -27.78 to -20.58
SecondaryPercentage Change From Baseline in Non-HDL-C at Week 4

Serum Non-HDL-C calculated at baseline and after 4 weeks of study drug administration. Non-HDL-C values were calculated as follows: Non-HDL-C (mg/dL) = TC - HDL-C.

Time frame:
Baseline and Week 4
Reported as:
Least squares mean · Percentage Change
Percentage Change From Baseline in Non-HDL-C at Week 4
Percentage ChangeEzetimibePlacebo
Percentage Change From Baseline in Non-HDL-C at Week 4-24.94 (-27.75 to -22.14)-0.33 (-3.88 to 3.22)
Statistical analysis
  • Ezetimibe vs Placebo · ANCOVA · p = <0.001 · Difference in least-squares means: -24.61 · 95% CI -28.06 to -21.16
SecondaryPercentage Change From Baseline in Non-HDL-C at Week 8

Serum Non-HDL-C calculated at baseline and after 8 weeks of study drug administration. Non-HDL-C values were calculated as follows: Non-HDL-C (mg/dL) = TC - HDL-C.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · Percentage Change
Percentage Change From Baseline in Non-HDL-C at Week 8
Percentage ChangeEzetimibePlacebo
Percentage Change From Baseline in Non-HDL-C at Week 8-25.41 (-28.37 to -22.45)1.14 (-2.63 to 4.92)
Statistical analysis
  • Ezetimibe vs Placebo · ANCOVA · p = <0.001 · Difference in least-squares means: -26.55 · 95% CI -30.35 to -22.75
SecondaryPercentage Change From Baseline in TG at Week 2

Serum TG levels measured using enzymatic methods at baseline and after 2 weeks of study drug administration.

Time frame:
Baseline and Week 2
Reported as:
Least squares mean · Percentage Change
Percentage Change From Baseline in TG at Week 2
Percentage ChangeEzetimibePlacebo
Percentage Change From Baseline in TG at Week 2-3.90 (-10.66 to 3.37)5.83 (-4.76 to 17.59)
Statistical analysis
  • Ezetimibe vs Placebo · Constrained longitudinal data analysis · p = 0.137 · Difference in least-squares means: -9.73 · 95% CI -22.73 to 3.27
SecondaryPercentage Change From Baseline in TG at Week 4

Serum TG levels measured using enzymatic methods at baseline and after 4 weeks of study drug administration.

Time frame:
Baseline and Week 4
Reported as:
Least squares mean · Percentage Change
Percentage Change From Baseline in TG at Week 4
Percentage ChangeEzetimibePlacebo
Percentage Change From Baseline in TG at Week 4-5.54 (-11.05 to 0.31)9.65 (0.60 to 19.53)
Statistical analysis
  • Ezetimibe vs Placebo · Constrained longitudinal data analysis · p = 0.005 · Difference in least-squares means: -15.19 · 95% CI -26.05 to -4.34
SecondaryPercentage Change From Baseline in TG at Week 8

Serum TG levels measured using enzymatic methods at baseline and after 8 weeks of study drug administration.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · Percentage Change
Percentage Change From Baseline in TG at Week 8
Percentage ChangeEzetimibePlacebo
Percentage Change From Baseline in TG at Week 8-9.99 (-16.28 to -3.21)-1.38 (-11.02 to 9.31)
Statistical analysis
  • Ezetimibe vs Placebo · Constrained longitudinal data analysis · p = 0.149 · Difference in least-squares means: -8.61 · 95% CI -20.44 to 3.23
SecondaryPercentage Change From Baseline in Apolipoprotein A-I (Apo A-I) at Week 12

Serum Apo A-I levels measured at baseline and after 12 weeks of study drug administration.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Percentage Change
Percentage Change From Baseline in Apolipoprotein A-I (Apo A-I) at Week 12
Percentage ChangeEzetimibePlacebo
Percentage Change From Baseline in Apolipoprotein A-I (Apo A-I) at Week 121.80 (-1.86 to 5.46)3.71 (-0.87 to 8.30)
Statistical analysis
  • Ezetimibe vs Placebo · ANCOVA · p = 0.373 · Difference in least-squares means: -1.91 · 95% CI -6.15 to 2.32
SecondaryPercentage Change From Baseline in TC:HDL-C Ratio at Week 2

Serum TC:HDL-C Ratio calculated at baseline and after 2 weeks of study drug administration.

Time frame:
Baseline and Week 2
Reported as:
Least squares mean · Percentage Change
Percentage Change From Baseline in TC:HDL-C Ratio at Week 2
Percentage ChangeEzetimibePlacebo
Percentage Change From Baseline in TC:HDL-C Ratio at Week 2-17.21 (-21.08 to -13.34)2.56 (-2.37 to 7.48)
Statistical analysis
  • Ezetimibe vs Placebo · ANCOVA · p = <0.001 · Difference in least-squares mean: -19.76 · 95% CI -24.70 to -14.82
SecondaryPercentage Change From Baseline in TC:HDL-C Ratio at Week 4

Serum TC:HDL-C Ratio calculated at baseline and after 4 weeks of study drug administration.

Time frame:
Baseline and Week 4
Reported as:
Least squares mean · Percentage Change
Percentage Change From Baseline in TC:HDL-C Ratio at Week 4
Percentage ChangeEzetimibePlacebo
Percentage Change From Baseline in TC:HDL-C Ratio at Week 4-19.36 (-23.16 to -15.56)1.48 (-3.30 to 6.25)
Statistical analysis
  • Ezetimibe vs Placebo · ANCOVA · p = <0.001 · Difference in least-squares means: -20.83 · 95% CI -25.59 to -16.07
SecondaryPercentage Change From Baseline in TC:HDL-C Ratio at Week 8

Serum TC:HDL-C Ratio calculated at baseline and after 8 weeks of study drug administration.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · Percentage Change
Percentage Change From Baseline in TC:HDL-C Ratio at Week 8
Percentage ChangeEzetimibePlacebo
Percentage Change From Baseline in TC:HDL-C Ratio at Week 8-20.07 (-24.20 to -15.94)3.41 (-1.87 to 8.70)
Statistical analysis
  • Ezetimibe vs Placebo · ANCOVA · p = <0.001 · Difference in least-squares means: -23.48 · 95% CI -29.00 to -17.97
SecondaryPercentage Change From Baseline in TC:HDL-C Ratio at Week 12

Serum TC:HDL-C Ratio calculated at baseline and after 12 weeks of study drug administration.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Percentage Change
Percentage Change From Baseline in TC:HDL-C Ratio at Week 12
Percentage ChangeEzetimibePlacebo
Percentage Change From Baseline in TC:HDL-C Ratio at Week 12-21.09 (-24.98 to -17.19)1.20 (-3.70 to 6.11)
Statistical analysis
  • Ezetimibe vs Placebo · ANCOVA · p = <0.001 · Difference in least-squares means: -22.29 · 95% CI -27.25 to -17.34
SecondaryPercentage Change From Baseline in LDL-C:HDL-C Ratio at Week 2

Serum LDL-C:HDL-C Ratio calculated at baseline and after 2 weeks of study drug administration.

Time frame:
Baseline and Week 2
Reported as:
Least squares mean · Percentage Change
Percentage Change From Baseline in LDL-C:HDL-C Ratio at Week 2
Percentage ChangeEzetimibePlacebo
Percentage Change From Baseline in LDL-C:HDL-C Ratio at Week 2-23.35 (-27.69 to -19.01)1.15 (-4.35 to 6.65)
Statistical analysis
  • Ezetimibe vs Placebo · ANCOVA · p = <0.001 · Difference in least-squares means: -24.50 · 95% CI -29.88 to -19.12
SecondaryPercentage Change From Baseline in LDL-C:HDL-C Ratio at Week 4

Serum LDL-C:HDL-C Ratio calculated at baseline and after 4 weeks of study drug administration.

Time frame:
Baseline and Week 4
Reported as:
Least squares mean · Percentage Change
Percentage Change From Baseline in LDL-C:HDL-C Ratio at Week 4
Percentage ChangeEzetimibePlacebo
Percentage Change From Baseline in LDL-C:HDL-C Ratio at Week 4-25.72 (-30.12 to -21.33)-0.57 (-6.14 to 5.00)
Statistical analysis
  • Ezetimibe vs Placebo · ANCOVA · p = <0.001 · Difference in least-squares means: -25.15 · 95% CI -30.69 to -19.62
SecondaryPercentage Change From Baseline in LDL-C:HDL-C Ratio at Week 8

Serum LDL-C:HDL-C Ratio calculated at baseline and after 8 weeks of study drug administration.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · Percentage Change
Percentage Change From Baseline in LDL-C:HDL-C Ratio at Week 8
Percentage ChangeEzetimibePlacebo
Percentage Change From Baseline in LDL-C:HDL-C Ratio at Week 8-26.43 (-31.21 to -21.66)2.87 (-3.28 to 9.02)
Statistical analysis
  • Ezetimibe vs Placebo · ANCOVA · p = <0.001 · Difference in least-squares means: -29.31 · 95% CI -35.71 to -22.91
SecondaryPercentage Change From Baseline in LDL-C:HDL-C Ratio at Week 12

Serum LDL-C:HDL-C Ratio calculated at baseline and after 12 weeks of study drug administration.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Percentage Change
Percentage Change From Baseline in LDL-C:HDL-C Ratio at Week 12
Percentage ChangeEzetimibePlacebo
Percentage Change From Baseline in LDL-C:HDL-C Ratio at Week 12-28.01 (-32.65 to -23.36)0.34 (-5.57 to 6.25)
Statistical analysis
  • Ezetimibe vs Placebo · ANCOVA · p = <0.001 · Difference in least-squares means: -28.35 · 95% CI -34.41 to -22.29
SecondaryPercentage Change From Baseline in Apo B:Apo A-I Ratio at Week 12

Serum Apo B:Apo A-I Ratio calculated at baseline and after 12 weeks of study drug administration

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Percentage Change
Percentage Change From Baseline in Apo B:Apo A-I Ratio at Week 12
Percentage ChangeEzetimibePlacebo
Percentage Change From Baseline in Apo B:Apo A-I Ratio at Week 12-22.16 (-26.13 to -18.19)-2.87 (-7.84 to 2.09)
Statistical analysis
  • Ezetimibe vs Placebo · ANCOVA · p = <0.001 · Difference in least-squares means: -19.28 · 95% CI -23.87 to -14.70
SecondaryPercentage Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) at Week 4

Plasma hs-CRP measured at baseline and after 4 weeks of study drug administration.

Time frame:
Baseline and Week 4
Reported as:
Least squares mean · Percentage Change
Percentage Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) at Week 4
Percentage ChangeEzetimibePlacebo
Percentage Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) at Week 410.00 (-15.65 to 43.45)56.11 (7.68 to 126.32)
Statistical analysis
  • Ezetimibe vs Placebo · Constrained longitudinal data analysis · p = 0.116 · Difference in least-squares means: -46.11 · 95% CI -108.14 to 15.92
SecondaryPercentage Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) at Week 12

Plasma hs-CRP measured at baseline and after 12 weeks of study drug administration.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Percentage Change
Percentage Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) at Week 12
Percentage ChangeEzetimibePlacebo
Percentage Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) at Week 129.35 (-13.47 to 38.19)-7.92 (-33.48 to 27.46)
Statistical analysis
  • Ezetimibe vs Placebo · Constrained longitudinal data analysis · p = 0.382 · Difference in least-squares means: 17.27 · 95% CI -20.46 to 55.00
SecondaryPercent Change From Baseline in Sitosterol at Week 2

Plasma sitosterol measured at baseline and after 2 weeks of study drug administration.

Time frame:
Baseline and Week 2
Reported as:
Least squares mean · Percentage Change
Percent Change From Baseline in Sitosterol at Week 2
Percentage ChangeEzetimibePlacebo
Percent Change From Baseline in Sitosterol at Week 2-50.20 (-54.65 to -45.76)-0.59 (-6.26 to 5.08)
Statistical analysis
  • Ezetimibe vs Placebo · ANCOVA · p = <0.001 · Difference in least-squares means: -49.61 · 95% CI -55.36 to -43.87
SecondaryPercentage Change From Baseline in Sitosterol at Week 4

Plasma sitosterol measured at baseline and after 4 weeks of study drug administration.

Time frame:
Baseline and Week 4
Reported as:
Least squares mean · Percentage Change
Percentage Change From Baseline in Sitosterol at Week 4
Percentage ChangeEzetimibePlacebo
Percentage Change From Baseline in Sitosterol at Week 4-58.82 (-63.04 to -54.61)-0.30 (-5.52 to 4.93)
Statistical analysis
  • Ezetimibe vs Placebo · ANCOVA · p = <0.001 · Difference in least-squares means: -58.52 · 95% CI -63.67 to -53.38
SecondaryPercentage Change From Baseline in Sitosterol at Week 8

Plasma sitosterol measured at baseline and after 8 weeks of study drug administration.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · Percentage Change
Percentage Change From Baseline in Sitosterol at Week 8
Percentage ChangeEzetimibePlacebo
Percentage Change From Baseline in Sitosterol at Week 8-61.59 (-66.39 to -56.78)-0.57 (-6.69 to 5.56)
Statistical analysis
  • Ezetimibe vs Placebo · ANCOVA · p = <0.001 · Difference in least-squares means: -61.02 · 95% CI -67.51 to -54.53
SecondaryPercentage Change From Baseline in Sitosterol at Week 12

Plasma sitosterol measured at baseline and after 12 weeks of study drug administration.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Percentage Change
Percentage Change From Baseline in Sitosterol at Week 12
Percentage ChangeEzetimibePlacebo
Percentage Change From Baseline in Sitosterol at Week 12-60.65 (-67.39 to -53.92)2.09 (-7.01 to 11.18)
Statistical analysis
  • Ezetimibe vs Placebo · ANCOVA · p = 0.001 · Difference in least-squares means: -62.74 · 95% CI -73.22 to -52.26
SecondaryPercentage Change From Baseline in Campesterol at Week 2

Plasma campesterol measured at baseline and after 2 weeks of study drug administration.

Time frame:
Baseline and Week 2
Reported as:
Least squares mean · Percentage Change
Percentage Change From Baseline in Campesterol at Week 2
Percentage ChangeEzetimibePlacebo
Percentage Change From Baseline in Campesterol at Week 2-53.87 (-57.99 to -49.74)-4.38 (-9.66 to 0.90)
Statistical analysis
  • Ezetimibe vs Placebo · ANCOVA · p = <0.001 · Difference in least-squares means: -49.48 · 95% CI -54.83 to -44.14
SecondaryPercentage Change From Baseline in Campesterol at Week 4

Plasma campesterol measured at baseline and after 4 weeks of study drug administration.

Time frame:
Baseline and Week 4
Reported as:
Least squares mean · Percentage Change
Percentage Change From Baseline in Campesterol at Week 4
Percentage ChangeEzetimibePlacebo
Percentage Change From Baseline in Campesterol at Week 4-62.27 (-66.21 to -58.32)-4.28 (-9.20 to 0.65)
Statistical analysis
  • Ezetimibe vs Placebo · ANCOVA · p = <0.001 · Difference in least-squares means: -57.99 · 95% CI -62.87 to -53.11
SecondaryPercentage Change From Baseline in Campesterol at Week 8

Plasma campesterol measured at baseline and after 8 weeks of study drug administration.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · Percentage Change
Percentage Change From Baseline in Campesterol at Week 8
Percentage ChangeEzetimibePlacebo
Percentage Change From Baseline in Campesterol at Week 8-66.79 (-71.21 to -62.37)-4.19 (-9.83 to 1.45)
Statistical analysis
  • Ezetimibe vs Placebo · ANCOVA · p = <0.001 · Difference in least-squares means: -62.60 · 95% CI -68.54 to -56.66
SecondaryPercentage Change From Baseline in Campesterol at Week 12

Plasma campesterol measured at baseline and after 12 weeks of study drug administration.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Percentage Change
Percentage Change From Baseline in Campesterol at Week 12
Percentage ChangeEzetimibePlacebo
Percentage Change From Baseline in Campesterol at Week 12-67.59 (-73.68 to -61.50)-2.92 (-11.15 to 5.31)
Statistical analysis
  • Ezetimibe vs Placebo · ANCOVA · p = <0.001 · Difference in least-squares means: -64.67 · 95% CI -74.11 to -55.23
SecondaryPercentage Change From Baseline in Cholestanol at Week 2

Plasma cholestanol measured at baseline and after 2 weeks of study drug administration.

Time frame:
Baseline and Week 2
Reported as:
Least squares mean · Percentage Change
Percentage Change From Baseline in Cholestanol at Week 2
Percentage ChangeEzetimibePlacebo
Percentage Change From Baseline in Cholestanol at Week 2-25.44 (-30.30 to -20.59)-7.09 (-13.29 to -0.90)
Statistical analysis
  • Ezetimibe vs Placebo · ANCOVA · p = <0.001 · Difference in least-squares means: -18.35 · 95% CI -24.70 to -11.99
SecondaryPercentage Change From Baseline in Cholestanol at Week 4

Plasma cholestanol measured at baseline and after 4 weeks of study drug administration.

Time frame:
Baseline and Week 4
Reported as:
Least squares mean · Percentage Change
Percentage Change From Baseline in Cholestanol at Week 4
Percentage ChangeEzetimibePlacebo
Percentage Change From Baseline in Cholestanol at Week 4-27.40 (-31.95 to -22.85)-1.79 (-7.42 to 3.85)
Statistical analysis
  • Ezetimibe vs Placebo · ANCOVA · p = <0.001 · Difference in least-squares means: -25.61 · 95% CI -31.20 to -20.02
SecondaryPercentage Change From Baseline in Cholestanol at Week 8

Plasma cholestanol measured at baseline and after 8 weeks of study drug administration.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · Percentage Change
Percentage Change From Baseline in Cholestanol at Week 8
Percentage ChangeEzetimibePlacebo
Percentage Change From Baseline in Cholestanol at Week 8-29.19 (-33.98 to -24.39)-0.44 (-6.44 to 5.56)
Statistical analysis
  • Ezetimibe vs Placebo · ANCOVA · p = <0.001 · Difference in least-squares means: -28.74 · 95% CI -34.89 to -22.59
SecondaryPercentage Change From Baseline in Cholestanol at Week 12

Plasma cholestanol measured at baseline and after 12 weeks of study drug administration.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Percentage Change
Percentage Change From Baseline in Cholestanol at Week 12
Percentage ChangeEzetimibePlacebo
Percentage Change From Baseline in Cholestanol at Week 12-28.71 (-34.44 to -22.99)3.42 (-4.07 to 10.92)
Statistical analysis
  • Ezetimibe vs Placebo · ANCOVA · p = <0.001 · Difference in least-squares means: -32.14 · 95% CI -40.38 to -23.90
SecondaryPercentage Change From Baseline in Lathosterol at Week 2

Plasma lathosterol measured at baseline and after 2 weeks of study drug administration.

Time frame:
Baseline and Week 2
Reported as:
Least squares mean · Percentage Change
Percentage Change From Baseline in Lathosterol at Week 2
Percentage ChangeEzetimibePlacebo
Percentage Change From Baseline in Lathosterol at Week 234.07 (24.68 to 43.45)14.06 (2.22 to 25.90)
Statistical analysis
  • Ezetimibe vs Placebo · ANCOVA · p = 0.001 · Difference in least-squares means: 20.01 · 95% CI 8.10 to 31.91
SecondaryPercentage Change From Baseline in Lathosterol at Week 4

Plasma lathosterol measured at baseline and after 4 weeks of study drug administration.

Time frame:
Baseline and Week 4
Reported as:
Least squares mean · Percentage Change
Percentage Change From Baseline in Lathosterol at Week 4
Percentage ChangeEzetimibePlacebo
Percentage Change From Baseline in Lathosterol at Week 433.02 (23.44 to 42.60)6.73 (-5.27 to 18.73)
Statistical analysis
  • Ezetimibe vs Placebo · ANCOVA · p = <0.001 · Difference in least-squares means: 26.29 · 95% CI 13.99 to 38.58
SecondaryPercentage Change From Baseline in Lathosterol at Week 8

Plasma lathosterol measured at baseline and after 8 weeks of study drug administration.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · Percentage Change
Percentage Change From Baseline in Lathosterol at Week 8
Percentage ChangeEzetimibePlacebo
Percentage Change From Baseline in Lathosterol at Week 835.87 (26.14 to 45.61)-0.82 (-12.99 to 11.34)
Statistical analysis
  • Ezetimibe vs Placebo · ANCOVA · p = <0.001 · Difference in least-squares means: 36.70 · 95% CI 24.12 to 49.28
SecondaryPercentage Change From Baseline in Lathosterol at Week 12

Plasma lathosterol measured at baseline and after 12 weeks of study drug administration.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Percentage Change
Percentage Change From Baseline in Lathosterol at Week 12
Percentage ChangeEzetimibePlacebo
Percentage Change From Baseline in Lathosterol at Week 1236.62 (26.46 to 46.78)12.57 (-0.36 to 25.50)
Statistical analysis
  • Ezetimibe vs Placebo · ANCOVA · p = <0.001 · Difference in least-squares means: 24.05 · 95% CI 10.43 to 37.67

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ezetimibe—2/92 (2.2%)27/92 (29.3%)
Placebo—0/45 (0%)18/45 (40%)
Most frequent serious events
Most frequent serious events
EventEzetimibePlacebo
Epilepsy congenitalCongenital, familial and genetic disorders1/920/45
AppendicitisInfections and infestations1/920/45
Most frequent other events
Most frequent other events
EventEzetimibePlacebo
HeadacheNervous system disorders4/926/45
Abdominal painGastrointestinal disorders4/925/45
NasopharyngitisInfections and infestations10/925/45
DiarrhoeaGastrointestinal disorders1/924/45
Upper respiratory tract infectionInfections and infestations7/921/45
NauseaGastrointestinal disorders1/923/45
VomitingGastrointestinal disorders2/923/45
InfluenzaInfections and infestations5/923/45

Baseline characteristics

Age, Continuous
Age, Continuous(years)EzetimibePlaceboTotal
Mean8.2 ± 1.78.5 ± 1.68.3 ± 1.6
Sex: Female, Male
Sex: Female, Male(Participants)EzetimibePlaceboTotal
Female522779
Male411859
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Kusters DM, Caceres M, Coll M, Cuffie C, Gagne C, Jacobson MS, Kwiterovich PO, Lee R, Lowe RS, Massaad R, McCrindle BW, Musliner TA, Triscari J, Kastelein JJ. Efficacy and safety of ezetimibe monotherapy in children with heterozygous familial or nonfamilial hypercholesterolemia. J Pediatr. 2015 Jun;166(6):1377-84.e1-3. doi: 10.1016/j.jpeds.2015.02.043. Epub 2015 Apr 1. PubMed 25841542 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2009 to primary completion in Apr 2012, 34 months.

Results were first posted in May 2013, 1 year 1 month after primary completion.

Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 34 months is above that.

Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2009
First posted
Mar 23, 2009
StartActual
May 21, 2009
Primary completionActual
Apr 13, 2012
CompletionActual
Apr 13, 2012
Results first posted
May 30, 2013
Last update
May 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00867165
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Mar 23, 2009
Start date
May 21, 2009
Primary completion
Apr 13, 2012
Completion
Apr 13, 2012
Results posted
May 30, 2013
Last update
May 21, 2024

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ezetimibe

Start the discussion